OTCMKTS:GNMSF Genmab A/S (GNMSF) Stock Price, News & Analysis → The asset beating inflation by 4x (From Colonial Metals) (Ad) Free GNMSF Stock Alerts $289.74 +13.27 (+4.80%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$282.69▼$301.3750-Day Range$269.87▼$313.0052-Week Range$262.00▼$426.50Volume375 shsAverage Volume625 shsMarket CapitalizationN/AP/E Ratio30.09Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Genmab A/S alerts: Email Address Ad Colonial MetalsThe asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.That's why we have released our Free Precious Metals Investment Guide that explains all the details About Genmab A/S Stock (OTCMKTS:GNMSF)Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Read More GNMSF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNMSF Stock News HeadlinesMay 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Genmab on Strong TIVDAK Approval and Promising Pipeline ValuationMay 1, 2024 | finance.yahoo.comComstock Inc (LODE) Q1 2024 Earnings Call Transcript Highlights: Strategic Investments and ...May 4, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).May 1, 2024 | americanbankingnews.comGenmab A/S (OTCMKTS:GNMSF) Sees Large Growth in Short InterestApril 16, 2024 | seekingalpha.comGenmab Acquires A Missing Piece For Its PipelineApril 16, 2024 | markets.businessinsider.comGenmab's Q1 Darzalex Sales By Johnson & Johnson Reach $2.692 BlnApril 9, 2024 | markets.businessinsider.comTruist Financial Keeps Their Buy Rating on Genmab (GMAB)April 8, 2024 | benzinga.comProfoundBio discovers the joys of having a wealthy ownerMay 4, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).March 17, 2024 | finance.yahoo.com30 Biggest Biotechnology Companies in the WorldMarch 13, 2024 | finance.yahoo.comPassing of Genmab A/S’ Annual General MeetingFebruary 21, 2024 | seekingalpha.comGenmab: Recent Updates Support The Growth NarrativeFebruary 20, 2024 | markets.businessinsider.com4 Analysts Assess Genmab: What You Need To KnowFebruary 15, 2024 | msn.comGenmab A/S’ New Regulation Risk – A Cause for Worry?February 15, 2024 | finance.yahoo.comGenmab A/S (NASDAQ:GMAB) Q4 2023 Earnings Call TranscriptFebruary 15, 2024 | finance.yahoo.comNotice to Convene the Annual General Meeting of Genmab A/SFebruary 14, 2024 | finance.yahoo.comGenmab Files Annual Report with the U.S. Securities and Exchange CommissionFebruary 14, 2024 | finance.yahoo.comGenmab: Growth Is Still a Better ChoiceFebruary 2, 2024 | finance.yahoo.comTisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical CancerJanuary 29, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For GenmabJanuary 25, 2024 | finance.yahoo.comGrant of Restricted Stock Units and Warrants to Employees in GenmabJanuary 22, 2024 | finance.yahoo.comGenmab Announces Decision in Arbitration Appeal under License Agreement with JanssenDecember 7, 2023 | finance.yahoo.comHRMY or GMAB: Which Is the Better Value Stock Right Now?November 8, 2023 | finance.yahoo.comGenmab A/S (NASDAQ:GMAB) Q3 2023 Earnings Call TranscriptNovember 7, 2023 | msn.comGenmab reports 9M resultsNovember 7, 2023 | finance.yahoo.comGenmab Announces Financial Results for the First Nine Months of 2023November 2, 2023 | finance.yahoo.comGenmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)See More Headlines Receive GNMSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:GNMSF CUSIPN/A CIK1434265 Webwww.genmab.com Phone(457) 020-2728Fax45-7020-2729Employees2,204Year Founded1999Profitability EPS (Most Recent Fiscal Year)$9.63 Trailing P/E Ratio30.09 Forward P/E RatioN/A P/E GrowthN/ANet Income$631.91 million Net Margins26.50% Pretax Margin34.22% Return on Equity18.06% Return on Assets16.13% Debt Debt-to-Equity RatioN/A Current Ratio13.34 Quick Ratio13.32 Sales & Book Value Annual Sales$2.39 billion Price / SalesN/A Cash Flow$13.54 per share Price / Cash Flow21.40 Book Value$59.44 per share Price / Book4.87Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.05 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Jan G.J. van de Winkel Ph.D. (Age 63)Co-Founder, President & CEO Comp: $2.88MMr. Anthony Pagano (Age 46)Executive VP & CFO Comp: $1.02MMs. Birgitte Stephensen M.Sc. (Age 63)Executive VP & Chief Legal Officer Comp: $632.67kDr. Martine J. van Vugt Ph.D. (Age 53)Executive VP & Chief Strategy Officer Comp: $690.19kMr. Martin Schultz (Age 48)Senior Director of Clinical Operations & Non-Independent Director Comp: $115.03kDr. Tahamtan Ahmadi (Age 51)Executive VP, Chief Medical Officer & Head of Experimental Medicines Comp: $1.11MDr. Mijke Zachariasse Ph.D. (Age 50)Senior Director, Head of Antibody Research Materials & Non-Independent Director Comp: $158.17kMr. Takahiro Hamatani (Age 49)Senior Director of Finance Japan & Non-Independent Director Comp: $115.03kMr. Anthony Mancini (Age 53)Executive VP & COO Comp: $1.09MMr. Andrew CarlsenSenior Director, VP & Head of Investor RelationsMore ExecutivesKey CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSAffymaxOTCMKTS:AFFYView All Competitors GNMSF Stock Analysis - Frequently Asked Questions How have GNMSF shares performed in 2024? Genmab A/S's stock was trading at $315.6999 at the beginning of the year. Since then, GNMSF stock has decreased by 8.2% and is now trading at $289.74. View the best growth stocks for 2024 here. Are investors shorting Genmab A/S? Genmab A/S saw a increase in short interest in April. As of April 15th, there was short interest totaling 169,700 shares, an increase of 7.3% from the March 31st total of 158,100 shares. Based on an average daily trading volume, of 1,000 shares, the days-to-cover ratio is presently 169.7 days. View Genmab A/S's Short Interest. How were Genmab A/S's earnings last quarter? Genmab A/S (OTCMKTS:GNMSF) released its quarterly earnings results on Wednesday, February, 14th. The company reported $3.63 earnings per share for the quarter. The firm had revenue of $675.29 million for the quarter. Genmab A/S had a net margin of 26.50% and a trailing twelve-month return on equity of 18.06%. How do I buy shares of Genmab A/S? Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:GNMSF) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024AltimetryThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.